U.S. Markets open in 5 hrs 47 mins
  • S&P Futures

    4,528.25
    +19.75 (+0.44%)
     
  • Dow Futures

    34,152.00
    +150.00 (+0.44%)
     
  • Nasdaq Futures

    15,921.50
    +51.75 (+0.33%)
     
  • Russell 2000 Futures

    2,164.00
    +17.70 (+0.82%)
     
  • Crude Oil

    66.22
    +0.65 (+0.99%)
     
  • Gold

    1,772.00
    -12.30 (-0.69%)
     
  • Silver

    22.33
    -0.01 (-0.06%)
     
  • EUR/USD

    1.1326
    +0.0004 (+0.0340%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Vix

    28.85
    +1.66 (+6.11%)
     
  • GBP/USD

    1.3292
    +0.0014 (+0.1077%)
     
  • USD/JPY

    113.2170
    +0.4370 (+0.3875%)
     
  • BTC-USD

    57,075.88
    -321.45 (-0.56%)
     
  • CMC Crypto 200

    1,454.69
    -14.39 (-0.98%)
     
  • FTSE 100

    7,120.63
    -48.05 (-0.67%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

MacroGenics to Participate in Upcoming Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in Cowen’s 2nd Annual Virtual Oncology Innovation Summit. MacroGenics’ management will participate in a fireside chat with the analyst on Thursday, May 20, 2021, at 9:20 am ET.

A webcast of the fireside chat may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company maintains archived replays of webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

CONTACT: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, info@macrogenics.com